Catch up on the weekend’s top five stories with this list compiled by The Fly: 1. The Wall Street Journal reported around 5 pm ET on Friday night that Intel (INTC) has worries about competition from a combined Qualcomm (QCOM) and Broadcom (AVGO) and may consider its own bid for Broadcom. Responding to Reuters following the Journal’s report, Intel said it does not comment on “rumors or speculation,” adding, “We have made important acquisitions over the past 30 months – including Mobileye and Altera – and our focus is on integrating those acquisitions and making them successful for our customers and shareholders.” 2. Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the Odyssey Outcomes trial met its primary endpoint, showing Praluent Injection “significantly reduced” the risk of major adverse cardiovascular events in patients who had suffered a recent acute coronary syndrome event, such as a heart attack. 3. Savara (SVRA) announced the Indie study of Aironite did not meet its primary endpoint of improvement in peak exercise capacity assessed by cardiopulmonary exercise testing, or its secondary endpoints. Following the negative outcome of the Indie study, Savara does not plan to support any new development of Aironite. 4. S&P Dow Jones Indices announced adjustments to the S&P 500, moving Take-Two Interactive Software (TTWO) and SVB Financial Group (SIVB) up from the S&P MidCap 400 to take the places of Signet Jewelers (SIG) and Patterson Companies (PDCO). 5. Campbell Soup (CPB), Altria Group (MO) and Molson Coors (TAP) were three consumer-staples names recommended as investments by Jack Hough of Barron’s.